A549-Luc

A549-Luc is a genetically engineered derivative of the human lung adenocarcinoma cell line A549, modified to stably express a luciferase reporter gene. The parental A549 cell line originates from a lung carcinoma of an adult patient and is widely used as a model for non-small cell lung cancer (NSCLC), particularly adenocarcinoma. A549 cells exhibit epithelial morphology and harbor key molecular features relevant to lung cancer biology, including mutations in KRAS and alterations in pathways regulating proliferation, metabolism, and response to oxidative stress. The luciferase-expressing variant retains these intrinsic characteristics while enabling bioluminescent detection.

The incorporation of the luciferase gene allows for sensitive, non-invasive quantification of viable cells through bioluminescence imaging following administration of a luciferin substrate. This enables real-time monitoring of cell proliferation, tumor growth, and therapeutic response in both in vitro assays and in vivo xenograft models. The emitted light signal correlates with metabolically active cell number, making A549-Luc particularly suitable for longitudinal studies of tumor kinetics, metastasis, and drug efficacy. Stable integration ensures sustained reporter expression, although signal intensity may vary depending on clone selection and experimental conditions.

A549-Luc maintains the biological behavior of the parental A549 line, including its utility in studies of lung cancer progression, inflammation, and response to chemotherapeutic or targeted agents. The addition of a luciferase reporter significantly enhances experimental flexibility, supporting high-throughput drug screening, in vivo imaging, and quantitative assessment of tumor burden over time. As such, A549-Luc is a valuable tool for translational lung cancer research and preclinical evaluation of novel therapeutic strategies.

37°C, 5% CO₂, humidified atmosphere.

1. Confirm that the vial remains deeply frozen upon delivery, as cells are shipped on dry ice to maintain optimal temperatures during transit.

2. Upon receipt, either store the cryovial immediately at temperatures below -150°C to ensure the preservation of cellular integrity, or proceed to step 3 if immediate culturing is required.

3. For immediate culturing, swiftly thaw the vial by immersing it in a 37°C water bath with clean water and an antimicrobial agent, agitating gently for 40-60 seconds until a small ice clump remains.

4. Perform all subsequent steps under sterile conditions in a flow hood, disinfecting the cryovial with 70% ethanol before opening.

5. Carefully open the disinfected vial and transfer the cell suspension into a 15 ml centrifuge tube containing 8 ml of room-temperature culture medium, mixing gently.

6. Centrifuge the mixture at 200 x g for 5 minutes, carefully discard the supernatant containing freezing medium.

7. Follow the procedure described under Post-Thaw Recovery

For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen.

Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage.

At Cytion, we stand behind the quality and viability of our products. We guarantee that our cells will be viable at the start of culture for 60 days after shipment from our facilities. We assure that all materials conform to the specifications described in the Certificate of Analysis and/or Product Sheet.

For full details, please refer to our Warranty Statement.